Results 191 to 200 of about 25,852 (233)
Some of the next articles are maybe not open access.
Selatogrel: A Novel Subcutaneous P2Y12 Inhibitor
Journal of Cardiovascular Pharmacology, 2022Abstract: The use of a P2Y12 inhibitor as a component of dual antiplatelet therapy in patients with an acute coronary syndrome (ACS) is well established. However, the P2Y12 inhibitors currently available have pharmacokinetic limitations due to delayed absorption, lack of enteral access for administration with oral formulations, need for ...
Craig J, Beavers +2 more
openaire +2 more sources
2023
Abstract Adenosine diphosphate P2Y12 receptor antagonists inhibit platelet activation and subsequent aggregation. These agents may be used either alone or as part of dual antiplatelet therapy regimens with aspirin. P2Y12 inhibitors have proven useful in the treatment and prevention of several atherosclerotic cardiovascular conditions ...
Manan Pareek, Deepak L. Bhatt
openaire +1 more source
Abstract Adenosine diphosphate P2Y12 receptor antagonists inhibit platelet activation and subsequent aggregation. These agents may be used either alone or as part of dual antiplatelet therapy regimens with aspirin. P2Y12 inhibitors have proven useful in the treatment and prevention of several atherosclerotic cardiovascular conditions ...
Manan Pareek, Deepak L. Bhatt
openaire +1 more source
Regulation of Functionally Active P2Y12 ADP Receptors by Thrombin in Human Smooth Muscle Cells and the Presence of P2Y12 in Carotid Artery Lesions [PDF]
Arteriosclerosis, Thrombosis, and Vascular Biology, 2010 Objective— The platelet P2Y12 ADP receptor is a well-known target of thienopyridine-type antiplatelet drugs.
Bernhard H Rauch +2 more
exaly +2 more sources
Current Opinion in Hematology, 2009
The P2Y12 antagonist clopidogrel has a well established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary syndromes. However, clopidogrel has a number of disadvantages that have led to the development of new P2Y12 antagonists.
openaire +2 more sources
The P2Y12 antagonist clopidogrel has a well established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary syndromes. However, clopidogrel has a number of disadvantages that have led to the development of new P2Y12 antagonists.
openaire +2 more sources
Role of P2Y12 Receptor in Thrombosis
2015P2Y12 receptor is a 342 amino acid Gi-coupled receptor predominantly expressed on platelets. P2Y12 receptor is physiologically activated by ADP and inhibits adenyl cyclase (AC) to decrease cyclic AMP (cAMP) level, resulting in platelet aggregation. It also activates PI3 kinase (PI3K) pathway leading to fibrinogen receptor activation, and may protect ...
Yaqi, Zhang, Si, Zhang, Zhongren, Ding
openaire +2 more sources
Characteristics of new P2Y12 inhibitors
Journal of Cardiovascular Medicine, 2013The options for antithrombotic therapy have recently been expanded, facilitating optimal tailored treatment. Dual antiplatelet therapy with aspirin and an approved adenosine diphosphate P2Y12 receptor antagonist is recommended for the management of patients with acute coronary syndromes (ACS).
openaire +2 more sources
State of the art of new P2Y12 antagonists
Internal and Emergency Medicine, 2010The interaction of ADP with its platelet receptor P2Y12 plays a crucial role in platelet activation and thrombogenesis. This article reviews the pharmacology and clinical trials of specific antagonists of P2Y12. Clopidogrel is a thienopyridine with proven antithrombotic efficacy, but it has some important drawbacks: (a) it is a pro-drug that needs to ...
M.N. Cattaneo, G. Podda
openaire +2 more sources
International Expert Consensus on Switching Platelet P2Y 12 Receptor–Inhibiting Therapies [PDF]
Circulation, 2017 Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor is the treatment of choice for the prevention of atherothrombotic events in patients with acute coronary syndromes and for those undergoing percutaneous coronary interventions. The availability
Dominick J Angiolillo +2 more
exaly +1 more source
P2Y12 receptors: structure and function
Journal of Thrombosis and Haemostasis, 2015The platelet P2Y12 receptor (P2Y12R) for adenosine 5'diphosphate (ADP) plays a central role in platelet function, hemostasis, and thrombosis. Patients with inherited P2Y12R defects display mild-to-moderate bleeding diatheses. Defects of P2Y12R should be suspected when ADP, even at high concentrations (≥ 10 μm), is unable to induce full, irreversible ...
openaire +3 more sources
Responsiveness to P2Y12 receptor inhibitors
Current Opinion in Cardiology, 2011This review is aimed at describing the variability in response to P2Y12 inhibitor agents, and to focus on the main tests currently available to assess the responsiveness.There is high interindividual response variability to clopidogrel. Some patients do not respond to the drug; this condition can be due to patient-related factors (poor compliance ...
openaire +3 more sources